scispace - formally typeset
Search or ask a question
Institution

European Society of Hypertension

OtherMilan, Italy
About: European Society of Hypertension is a other organization based out in Milan, Italy. It is known for research contribution in the topics: Blood pressure & Ambulatory blood pressure. The organization has 146 authors who have published 167 publications receiving 20150 citations.


Papers
More filters
Journal ArticleDOI
TL;DR: The 2018 European Society of Cardiology/European Society of Hypertension Guidelines for the management of arterial hypertension, do not recommend treatment to immediately lower BP in patients with acute ICH and systolic BP < 220 mmHg and careful lowering of SBP to less than 180 mm Hg via i.v. may be considered only in Patients with SBP, and aggressive BP control in the acute phase of ICH is not beneficial.
Abstract: Intracerebral haemorrhage (ICH) is a devastating cerebrovascular disease, which accounts to 15% of all strokes. Among modifiable risk factors for ICH, hypertension is the most frequent. High blood pressure (BP) is detected in more than 75–80% of patients with ICH. Extremely elevated BP has been associated with early hematoma growth, a relatively frequent occurrence and powerful predictor of poor outcome in patients with spontaneous ICH. On the other hand, excessively low BP might cause cerebral hypoperfusion and ultimately lead to poor outcome. This review will analyse the most important trials that have tried to establish how far should BP be lowered during acute ICH. These trials have demonstrated either a small non-significant benefit (INTERACT-2, INTEnsive blood pressure Reduction in Acute Cerebral haemorrhage Trial) or no benefit (ATACH-2, Antihypertensive treatment of acute cerebral haemorrhage II study) when intensive systolic BP reduction was compared with modest or standard BP reduction. The more recent meta-analyses including studies investigating this issue yielded similar conclusions: aggressive BP control in the acute phase of ICH is not beneficial. For these reasons the 2018 European Society of Cardiology/ European Society of Hypertension Guidelines for the management of arterial hypertension, do not recommend treatment to immediately lower BP in patients with acute ICH and systolic BP < 220 mmHg. Careful lowering of SBP to less than 180 mmHg via i.v. Infusion may be considered only in patients with SBP ≥ 220 mmHg.

5 citations

Journal ArticleDOI
01 Oct 2019
TL;DR: Die isolierte systolische Hypertonie (ISH) ist definiert als erhohter systolischer Blutdruck (BD) mit normalen oder niedrigen diastolischen Werten.
Abstract: Die isolierte systolische Hypertonie (ISH) ist definiert als erhohter systolischer Blutdruck (BD) mit normalen oder niedrigen diastolischen Werten: > 140/

4 citations

Journal ArticleDOI
TL;DR: The findings support the concept that aging is not necessarily synonymous with atherosclerosis and highlight the key role played by superimposed CV risk factors on arterial ‘‘bad aging’’.
Abstract: Age is traditionally considered a major cardiovascular (CV) risk factor, but its real weight in the absence of other modifiable risk factors is not clear. To compare the prevalence of subclinical carotid atherosclerosis, and its association with the main CV risk factors, between older adults and hypertensive adults. Cross-sectional study on 210 consecutive patients: 70 older adults (age ≥ 80 years), and 140 hypertensive adults having at least another CV risk factor. Patients had no history of peripheral artery disease or major CV events. Mean age was 54.2 ± 7.2 years in hypertensive adults and 88.5 ± 5.5 years in older adults with a female prevalence in the latter group. Dyslipidemia and smoking were more prevalent in hypertensive adults, while chronic kidney disease was more prevalent in older adults. Prevalence of carotid plaques did not differ between hypertensive adults and older adults (48.2% vs 55.6%, respectively, p = 0.311). Age ≥ 80 years was not associated with a higher risk of carotid plaques even after adjusting for other risk factors (p = 0.204). Hypertension and dyslipidemia were the risk factors more strongly associated with carotid plaques in older adults and hypertensive adults, respectively. When older adults with hypertension were excluded from the analysis, prevalence of carotid plaques was significantly higher in hypertensive adults (p = 0.042). Hypertension and dyslipidemia are the major determinant of atherosclerosis regardless of age in our study. Our findings support the concept that aging is not necessarily synonymous with atherosclerosis and highlight the key role played by superimposed CV risk factors on arterial ‘‘bad aging’’.

4 citations

Journal ArticleDOI
TL;DR: The Messung der aortalen Pulswellengeschwindigkeit (aPWV) as mentioned in this paper is ein direktes mas fur die arterielle Steifigkeits der Aorta and betragt bei normotensiven Gesunden altersabhangig 4-9m/s.
Abstract: Die Messung der aortalen Pulswellengeschwindigkeit (aPWV) ist ein direktes Mas fur die arterielle Steifigkeit der Aorta und betragt bei normotensiven Gesunden altersabhangig 4–9 m/s. Die aPWV besitzt uber klassische kardiovaskulare Risikofaktoren hinaus eine additive pradiktive Wertigkeit fur kardiovaskulare Ereignisse. Eine Erhohung der aPWV um 1 m/s ist mit einer Steigerung des kardiovaskularen Risikos bis zu 15 % verbunden. Die Unterscheidung zwischen kalzifizierender Arteriosklerose und nicht kalzifizierender Atherosklerose ist klinisch wichtig. Aus dem Befund einer erhohten Gefassteifigkeit kann nicht direkt auf das Vorliegen einer Atherosklerose, wie z. B. koronare Herzerkrankung, geschlossen werden. Als Goldstandard fur die Messung der aortalen Steifigkeit wird die Pulswellengeschwindigkeit zwischen Karotis und Femoralarterie angesehen. Bis weitere Studiendaten vorliegen, sollte bei Normotonie eine aPWV uber 10 m/s als pathologisch betrachtet werden. Viele der bereits auf dem Markt angebotenen Gerate zur Messung der Gefassteifigkeit zeigen eine noch unzureichende Standardisierung bezuglich Messmethode und Messgenauigkeit. Es sollte eine herstellerunabhangige, standardisierte Validierung gegen invasiven oder nichtinvasiven Goldstandard vorliegen sowie eine in epidemiologischen und prognostischen Studien belegte additive pradiktive Wertigkeit. Das wichtigste Therapieziel bei der Behandlung der arteriellen Gefassteifigkeit ist eine Normalisierung der Blutdruckwerte gemas aktueller ESH (European Society of Hypertension)-Leitlinien. Aufgrund langerfristiger Einflusse auf das vaskulare Remodeling sind nach heutigem Stand vermutlich Blocker des Renin-Angiotensin-Aldosteron-Systems am ehesten geeignet, eine uber reine Blutdruckeffekte hinausgehende Wirkung auf die Gefassteifigkeit zu erzielen. Inwieweit eine antihypertensive Therapie mit dem Zielparameter „Gefassteifigkeit“ sich daruber hinaus positiv auf harte kardiovaskulare Endpunkte auswirkt, ist Gegenstand zurzeit laufender Studien.

4 citations


Authors

Showing all 146 results

NameH-indexPapersCitations
Suzanne Oparil106885113983
Sverre E. Kjeldsen9473589059
Josep Redon7748881395
Eva Prescott7534946067
Renata Cifkova6830580868
Enrico Agabiti Rosei5220027518
Riccardo Sarzani371364724
Giovanni Cerasola321433355
Santina Cottone321483140
Paolo Dessì-Fulgheri31773810
Giuseppe Mulè311522984
Alessandro Rappelli291113112
Emilio Nardi27902130
Federico Guerra241411559
Giampiero Bricca21931592
Network Information
Related Institutions (5)
Vita-Salute San Raffaele University
22.4K papers, 953K citations

83% related

Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
15.4K papers, 434.4K citations

83% related

Mario Negri Institute for Pharmacological Research
13.2K papers, 829.1K citations

83% related

New York Medical College
18K papers, 681.8K citations

80% related

Seconda Università degli Studi di Napoli
21.6K papers, 546.7K citations

79% related

Performance
Metrics
No. of papers from the Institution in previous years
YearPapers
20219
202022
201915
201813
201711
201625